Arcus Biosciences, Inc. Lessee, Operating Lease, Liability, to be Paid, Year One
Arcus Biosciences, Inc. (RCUS) had Lessee, Operating Lease, Liability, to be Paid, Year One of $18.00 million as of 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Notes › Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths · last filed 2026-02-25
- 2025-12-31: Lessee, Operating Lease, Liability, to be Paid, Year One $18.00M.
- 2024-12-31: Lessee, Operating Lease, Liability, to be Paid, Year One $17.00M.
- 2023-12-31: Lessee, Operating Lease, Liability, to be Paid, Year One $17.00M.
- 2022-12-31: Lessee, Operating Lease, Liability, to be Paid, Year One $15.00M.
| Period end | Lessee, Operating Lease, Liability, to be Paid, Year One |
|---|---|
| 2025-12-31 | $18.00M 10-K · filed 2026-02-25 |
| 2024-12-31 | $17.00M 10-K · filed 2025-02-25 |
| 2023-12-31 | $17.00M 10-K · filed 2024-02-21 |
| 2022-12-31 | $15.00M 10-K · filed 2023-02-28 |
| 2021-12-31 | $11.20M 10-K · filed 2022-02-23 |
| 2021-09-30 | $5.72M 10-Q · filed 2021-11-08 |
| 2021-06-30 | $5.72M 10-Q · filed 2021-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |